The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

Human embryonic kidney (HEK293) cells are the most commonly used cell line to produce viral vectors for gene therapy. Due to the complexity of their production and purification, viral vectors can be ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Asimov’s LV Edge Packaging cell line routinely achieves high titers for therapeutic transgenes and is now available at AGC Biologics’ Cell and Gene Center of Excellence BOSTON & MILAN--(BUSINESS WIRE) ...

Viral vectors and vaccines navigate public distrust while advancing through AI design, COVID response lessons, and promising ...

Cell and gene therapies are changing lives. They engineer patients’ cells or DNA to create personalized therapies, unlocking long-lasting or even curative treatments for diseases with high unmet needs ...